• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.

作者信息

Pugliese Daniela, Privitera Giuseppe, Armuzzi Alessandro

机构信息

CEMAD - IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.

Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Aliment Pharmacol Ther. 2022 Aug;56(4):733-734. doi: 10.1111/apt.17076.

DOI:10.1111/apt.17076
PMID:35879901
Abstract
摘要

相似文献

1
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.社论：维多珠单抗在炎症性肠病老年和非老年匹配队列患者中的有效性和安全性——IG-IBD LIVE研究。作者回复。
Aliment Pharmacol Ther. 2022 Aug;56(4):733-734. doi: 10.1111/apt.17076.
2
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.社论：维多珠单抗在老年和非老年炎症性肠病患者配对队列中的有效性和安全性——IG-IBD LIVE研究
Aliment Pharmacol Ther. 2022 Aug;56(4):731-732. doi: 10.1111/apt.16957.
3
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.在炎症性肠病的老年和非老年患者匹配队列中，vedolizumab 的有效性和安全性：IG-IBD LIVE 研究。
Aliment Pharmacol Ther. 2022 Jul;56(1):95-109. doi: 10.1111/apt.16923. Epub 2022 May 12.
4
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.合并症而非患者年龄与 vedolizumab 和 ustekinumab 治疗的炎症性肠病患者安全性结局受损相关：一项前瞻性多中心队列研究。
Aliment Pharmacol Ther. 2020 Oct;52(8):1366-1376. doi: 10.1111/apt.16073. Epub 2020 Sep 9.
5
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply.社论：改善炎症性肠病青少年患者维多珠单抗药代动力学的成就与未解决的问题——作者回复
Aliment Pharmacol Ther. 2023 Mar;57(5):567-568. doi: 10.1111/apt.17337.
6
Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.社论：维多珠单抗治疗炎症性肠病——少即是多？作者回复。
Aliment Pharmacol Ther. 2021 Feb;53(3):445-446. doi: 10.1111/apt.16227.
7
Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.老年炎症性肠病患者使用维得利珠单抗与肿瘤坏死因子α拮抗剂的安全性和疗效：单中心回顾性经验。
Dig Dis Sci. 2022 Jul;67(7):3129-3137. doi: 10.1007/s10620-021-07129-5. Epub 2021 Jul 15.
8
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.小儿炎症性肠病中维得利珠单抗的应用：来自 ESPGHAN 小儿炎症性肠病波尔图小组的回顾性多中心经验。
J Crohns Colitis. 2017 Oct 1;11(10):1230-1237. doi: 10.1093/ecco-jcc/jjx082.
9
Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.维多珠单抗在全国老年炎症性肠病患者队列中的疗效。
Inflamm Bowel Dis. 2022 May 4;28(5):734-744. doi: 10.1093/ibd/izab163.
10
Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study.老年男性炎症性肠病患者使用维得利珠单抗、泼尼松和 5-ASA 药物后感染和恶性肿瘤的发生率：一项全国性回顾性队列研究。
Adv Ther. 2021 May;38(5):2586-2598. doi: 10.1007/s12325-021-01713-x. Epub 2021 Apr 12.